These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16775175)

  • 1. Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer.
    Faupel-Badger JM; Prindiville SA; Venzon D; Vonderhaar BK; Zujewski JA; Eng-Wong J
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1153-8. PubMed ID: 16775175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.
    Eng-Wong J; Hursting SD; Venzon D; Perkins SN; Zujewski JA
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1468-73. PubMed ID: 14693739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer.
    Johansson H; Bonanni B; Mariette F; Cazzaniga M; Baglietto L; Guerrieri-Gonzaga A; Sandri MT; Luini A; Pelosi G; Decensi A
    Breast Cancer Res Treat; 2006 Jul; 98(2):167-72. PubMed ID: 16538534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.
    Eliassen AH; Missmer SA; Tworoger SS; Spiegelman D; Barbieri RL; Dowsett M; Hankinson SE
    J Natl Cancer Inst; 2006 Oct; 98(19):1406-15. PubMed ID: 17018787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Kaaks R; Berrino F; Key T; Rinaldi S; Dossus L; Biessy C; Secreto G; Amiano P; Bingham S; Boeing H; Bueno de Mesquita HB; Chang-Claude J; Clavel-Chapelon F; Fournier A; van Gils CH; Gonzalez CA; Gurrea AB; Critselis E; Khaw KT; Krogh V; Lahmann PH; Nagel G; Olsen A; Onland-Moret NC; Overvad K; Palli D; Panico S; Peeters P; Quirós JR; Roddam A; Thiebaut A; Tjønneland A; Chirlaque MD; Trichopoulou A; Trichopoulos D; Tumino R; Vineis P; Norat T; Ferrari P; Slimani N; Riboli E
    J Natl Cancer Inst; 2005 May; 97(10):755-65. PubMed ID: 15900045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediagnostic Circulating Levels of Sex Steroid Hormones and SHBG in Relation to Risk of Ductal Carcinoma
    Arthur RS; Xue X; Rohan TE
    Cancer Epidemiol Biomarkers Prev; 2020 May; 29(5):1058-1066. PubMed ID: 32127398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women.
    Johansson H; Gandini S; Bonanni B; Mariette F; Guerrieri-Gonzaga A; Serrano D; Cassano E; Ramazzotto F; Baglietto L; Sandri MT; Decensi A
    Breast Cancer Res Treat; 2008 Mar; 108(1):57-67. PubMed ID: 17468953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premenopausal serum androgens and breast cancer risk: a nested case-control study.
    Zeleniuch-Jacquotte A; Afanasyeva Y; Kaaks R; Rinaldi S; Scarmo S; Liu M; Arslan AA; Toniolo P; Shore RE; Koenig KL
    Breast Cancer Res; 2012 Feb; 14(1):R32. PubMed ID: 22339988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of raloxifene on salivary sex steroid concentrations in premenopausal women.
    Chatterton RT; Zujewski J; Mateo ET; Eng-Wong J; Jordan VC
    J Endocrinol; 2006 Dec; 191(3):599-604. PubMed ID: 17170217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of sex hormones and breast cancer risk in premenopausal women: a case-control study (USA).
    Sturgeon SR; Potischman N; Malone KE; Dorgan JF; Daling J; Schairer C; Brinton LA
    Cancer Causes Control; 2004 Feb; 15(1):45-53. PubMed ID: 14970734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.
    Johansson H; Bonanni B; Gandini S; Guerrieri-Gonzaga A; Cazzaniga M; Serrano D; Macis D; Puccio A; Sandri MT; Gulisano M; Formelli F; Decensi A
    Breast Cancer Res Treat; 2013 Dec; 142(3):569-78. PubMed ID: 24241787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II.
    Fortner RT; Eliassen AH; Spiegelman D; Willett WC; Barbieri RL; Hankinson SE
    Breast Cancer Res; 2013 Mar; 15(2):R19. PubMed ID: 23497468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
    Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
    Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
    Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
    Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum estradiol level and risk of breast cancer during treatment with raloxifene.
    Cummings SR; Duong T; Kenyon E; Cauley JA; Whitehead M; Krueger KA;
    JAMA; 2002 Jan; 287(2):216-20. PubMed ID: 11779264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
    Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of raloxifene on normal breast tissue from premenopausal women.
    da Silva BB; Lopes IM; Gebrim LH
    Breast Cancer Res Treat; 2006 Jan; 95(2):99-103. PubMed ID: 16205837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.
    Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N
    Menopause; 2006; 13(5):787-92. PubMed ID: 16912660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.